Stryker Corporation (SYK) reported first-quarter 2024 adjusted earnings per share (EPS) of $2.50, which beat the Zacks Consensus Estimate of $2.35 by 6.4%. The bottom line also improved 16.8% year over year. GAAP EPS was $2.05, up 33.1% from the year-ago quarter’s level. Price Performance SYK’s shares have risen 19.5% year to date compared with the industry's growth of 6.7%. The S&P 500 Index has increased 10.1% in the same period. Image Source: Zacks Investment Research Revenue Details Revenues totaled $5. ...

财务数据和关键指标变化 - 第一季度有机销售增长10%,与去年同期相比增长13.6%,但由于少了一个销售日,影响了销售增长 [18] - 定价对销售的影响为正0.7%,公司在MedSurg和Neurotech业务中的定价举措持续产生积极影响 [18] - 汇率对销售的影响为负0.5% [18] - 第一季度美国有机销售增长11.3%,国际有机销售增长6.6%,与去年同期的16%相比有所放缓 [19] - 第一季度调整后每股收益为2.50美元,同比增长16.8%,主要得益于强劲的销售增长和毛利率扩张 [19] - 汇率对每股收益的不利影响为0.05美元 [19] 各条业务线数据和关键指标变化 MedSurg和Neurotechnology - 第一季度常汇率销售增长12%,有机销售增长11.6%,其中美国有机销售增长13.5%,国际有机销售增长6% [20] - Instruments业务美国有机销售增长19%,主要得益于手术吸烟装置、手术工具、Steri-Shield等产品的强劲表现 [20][21] - Endoscopy业务美国有机销售增长11.1%,主要得益于相机、光源、腹腔镜等产品的强劲表现 [21] - Medical业务美国有机销售增长16.8%,主要得益于担架、急救车、Vocera和Sage等产品的强劲表现 [21] - Neurovascular业务美国有机销售增长2.9%,主要得益于出血性血管支架和导丝的良好表现 [22] - Neuro Cranial业务美国有机销售增长7%,主要得益于CMF业务的强劲表现 [22] Orthopaedics和Spine - 第一季度常汇率和有机销售均增长8%,其中美国有机销售增长8.3%,国际有机销售增长7.4% [22] - 美国髋关节业务有机销售增长6.8%,主要得益于Insignia髋杆的强劲表现 [23] - 美国膝关节业务有机销售增长3.1%,主要得益于机器人辅助膝关节手术的市场领先地位和安装基数的持续强劲 [23] - 美国创伤和四肢业务有机销售增长10.3%,主要得益于上肢、生物材料和核心创伤业务的强劲表现 [23] - 美国脊柱业务有机销售增长3.9%,主要得益于介入脊柱业务的良好表现 [23] - 美国其他骨科业务有机销售增长45.6%,主要得益于Mako机器人安装量的大幅增加 [24] - 国际Orthopaedics和Spine业务有机销售增长7.4%,主要得益于加拿大和大部分新兴市场的强劲表现,尤其是Mako机器人安装量的大幅增加 [24] 各个市场数据和关键指标变化 - 美国市场第一季度有机销售增长11.3%,国际市场有机销售增长6.6%,与去年同期的16%相比有所放缓 [19] - 国际市场中,英国和加拿大以及大部分新兴市场表现良好 [19] - 国际市场中,拉丁美洲市场仍然是一个大机会,公司正在调整自身结构以更好地抓住这一机会 [110] 公司战略和发展方向及行业竞争 - 公司完成了对mfPHD的收购,这进一步增强了内窥镜业务部门的通信业务单元组合,帮助公司满足客户对手术室设计和建设的整体需求 [8] - 公司还完成了对SERF公司的收购,这是在髋关节业务中的一项收购 [8] - 公司的并购管线很强劲,预计今年将保持较高的并购活跃度 [8] - 公司在人才和文化建设方面的持续投入,使其连续14年被评为《财富》杂志100家最佳工作公司之一,这是公司的核心竞争力 [10] - 公司最近发布了第四份年度综合报告,涵盖了公司在企业责任方面的承诺和披露 [10] - 公司在机器人辅助手术、人口统计学、价格环境稳定以及患者活动健康等因素的驱动下,手术量保持强劲 [12] - 公司的资本产品需求保持健康,Endoscopy和Medical部门的订单备货维持在较高水平 [13] - 公司的Mako直接面向患者的营销活动表现出色,第一季度美国和国际市场的Mako安装量创历史新高,这将继续推动髋关节和膝关节业务的增长 [13][110] - 公司在创伤和四肢业务推出了Pangea钢板系统,这是该业务历史上最大的一次推出,将有助于实现更多医院的转换 [14] - 公司获得FDA批准推出新的LIFEPAK 35除颤监护仪,这是急救业务的旗舰产品,将在第二季度末推出,未来几年将为Medical部门带来利益 [15] - 公司计划在第四季度推出Mako、脊柱和CoPilot产品,以及年底推出肩关节应用,这些新技术受到外科医生的积极反馈 [16] 管理层对经营环境和未来前景的评论 - 公司预计全年有机销售增长将达到8.5%-9.5%,调整后每股收益将达到11.85-12.05美元,这体现了公司高增长的持久性,也是公司商业实力和广泛创新管线的证明 [9] - 公司有信心在2025年实现200个基点的营业利润率扩张目标 [9] - 公司认为,在当前市场环境下,这种高增长态势是可持续的,只要公司继续保持投资创新和并购高增长资产的节奏 [60] - 公司对国际市场,特别是新兴市场如印度、日本、部分欧洲国家以及韩国的发展前景持乐观态度,认为这些市场仍有很大的增长空间 [110]

Stryker (SYK) reported $5.24 billion in revenue for the quarter ended March 2024, representing a year-over- year increase of 9.7%. EPS of $2.50 for the same period compares to $2.14 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $5.05 billion, representing a surprise of +3.74%. The company delivered an EPS surprise of +6.38%, with the consensus EPS estimate being $2.35. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how t ...

Stryker (SYK) came out with quarterly earnings of $2.50 per share, beating the Zacks Consensus Estimate of $2.35 per share. This compares to earnings of $2.14 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 6.38%. A quarter ago, it was expected that this medical device maker would post earnings of $3.27 per share when it actually produced earnings of $3.46, delivering a surprise of 5.81%. Over the last four quarters, the com ...

Exhibit 99.1 STRYKER REPORTS FIRST QUARTER 2024 OPERATING RESULTS Portage, Michigan - April 30, 2024 - Stryker (NYSE:SYK) reported operating results for the first quarter of 2024: First Quarter Results • Reported net sales increased 9.7% to $5.2 billion • Organic net sales increased 10.0% • Reported operating income margin of 18.5% • Adjusted operating income margin(1) increased 80 bps to 21.9% • Reported EPS increased 33.1% to $2.05 • Adjusted EPS(1) increased 16.8% to $2.50 First Quarter Net Sales Growth ...

Stryker季度业绩预测 - 分析师预计Stryker将在即将发布的季度报告中每股盈利为2.35美元，同比增长9.8%[1] - 预计营收将达到50.6亿美元，同比增长5.8%[1] Stryker业务表现 - 分析师的平均预测显示，Stryker的多个关键业务领域的净销售额和地理区域的净销售额都有不同程度的增长[6]-[18] Stryker股票表现 - Stryker股票在过去一个月中下跌了6.1%，略低于Zacks S&P 500指数的-3%[19] - Stryker目前的Zacks排名为3（持有），预计将在短期内紧随整体市场表现[19]

The global orthopedic space has seen significant transformative changes in recent times. Major players like Stryker (SYK) and Zimmer Biomet (ZBH) have rapidly adopted differentiated strategies to make up for the lost growth during the pandemic. Both these S&P 500 players, who have started their 2024 journey on an optimistic note, are due to report first- quarter 2024 results in the upcoming week. Accordingly, it’s time for investors to revisit their quarter’s takeaway and assess the overall growth potential ...

Stryker Corporation (SYK) is scheduled to release first-quarter 2024 results on Apr 30, after market close. In the last reported quarter, the company delivered an earnings surprise of 5.81%. Q1 Estimates The Zacks Consensus Estimate for earnings is pegged at $2.35 per share, indicating an increase of 9.8% year over year. The consensus mark for revenues is pinned at $5.06 billion, implying growth of 5.8% from the prior-year quarter’s reported figure. Factors to Note Stryker's MedSurg and Neurotechnology segm ...

Stryker (SYK)盈利预测 - Stryker (SYK)预计在2024年3月报告的季度中，盈利将同比增长，收入也将增加[1] - 如果关键数据超过预期，股价可能会上涨，反之则可能下跌[2] - 分析师们最近对Stryker的盈利前景变得悲观，因此预计其盈利将低于预期[12] - Stryker在过去四个季度中四次超过了预期盈利[14] ResMed (RMD)盈利预测 - 预计ResMed (RMD)将在2024年3月报告的季度中，盈利将同比增长，但最近的盈利预期较低[18]

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Stryker (SYK) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Stryker is one of 1062 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks R ...